|
|
Blood, 15 November 2004, Vol. 104, No. 10, pp. 3355-3357.
Prepublished online as a Blood First Edition Paper on June 17, 2004; DOI 10.1182/blood-2003-11-3922.
 Previous Article | Next Article 
Submitted November 18, 2003
Accepted May 18, 2004
Elevated Serum Soluble Interleukin-2 Receptor Levels in Patients with Anaplastic Large Cell Lymphoma
John E Janik*, John C Morris, Stefania Pittaluga, Kristin McDonald, Mark Raffeld, Elaine S Jaffe, Nicole Grant, Martin Gutierrez, Thomas A Waldmann, and Wyndham H Wilson
Metabolism Branch, National Cancer Institute, Bethesda, MD, USA
Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA
Experimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD, USA
* Corresponding author; email: janikj{at}mail.nih.gov.
Serum soluble interleukin 2 receptor (sIL2R) levels provide a reliable marker of disease activity in patients with hairy cell leukemia and adult T-cell leukemia/lymphoma. The malignant cells in patients with anaplastic large cell lymphoma (ALCL) express CD30 and are usually positive for expression of CD25. We measured serum sIL2R and soluble CD30 (sCD30) levels in patients with ALCL treated with EPOCH infusional chemotherapy. Serum sCD30 levels were elevated and decreased in response to therapy as previously reported. Serum sIL2R levels were elevated in seven of nine patients with ALCL and decreased in response to treatment. Baseline serum sIL2R levels varied but correlated well with serum sCD30 levels (r=0.97). ALK positive cases showed elevated sIL2R levels whereas the ALK negative patients had normal serum sIL2R levels and their tumors lacked CD25 expression. Serum sIL2R levels were elevated in both patients with recurrent disease.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
G. Gualco, L. Chioato, L. M. Weiss, W. J. Harrington Jr, and C. E. Bacchi
Analysis of Human T-Cell Lymphotropic Virus in CD25+ Anaplastic Large Cell Lymphoma in Children
Am J Clin Pathol,
July 1, 2009;
132(1):
28 - 33.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Popov, J. Driesen, Z. Abdullah, C. Wickenhauser, M. Beyer, S. Debey-Pascher, T. Saric, S. Kummer, O. Takikawa, E. Domann, et al.
Infection of Myeloid Dendritic Cells with Listeria monocytogenes Leads to the Suppression of T Cell Function by Multiple Inhibitory Mechanisms
J. Immunol.,
October 1, 2008;
181(7):
4976 - 4988.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M.L. Ebos, C. R. Lee, E. Bogdanovic, J. Alami, P. Van Slyke, G. Francia, P. Xu, A. J. Mutsaers, D. J. Dumont, and R. S. Kerbel
Vascular Endothelial Growth Factor Mediated Decrease in Plasma Soluble Vascular Endothelial Growth Factor Receptor-2 Levels as a Surrogate Biomarker for Tumor Growth
Cancer Res.,
January 15, 2008;
68(2):
521 - 529.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Zhang, Z. Yao, Z. Zhang, K. Garmestani, V. S. Talanov, P. S. Plascjak, S. Yu, H.-S. Kim, C. K. Goldman, C. H. Paik, et al.
The Anti-CD25 Monoclonal Antibody 7G7/B6, Armed with the {alpha}-Emitter 211At, Provides Effective Radioimmunotherapy for a Murine Model of Leukemia
Cancer Res.,
August 15, 2006;
66(16):
8227 - 8232.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Zhang, Z. Yao, Z. Zhang, K. Garmestani, C. K. Goldman, J. V. Ravetch, J. Janik, M. W. Brechbiel, and T. A. Waldmann
Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors
Blood,
July 15, 2006;
108(2):
705 - 710.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Jacobsen
Anaplastic Large-Cell Lymphoma, T-/Null-Cell Type
Oncologist,
July 1, 2006;
11(7):
831 - 840.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
